NFKB1 and lung carcinoma: In addition, other mutations affecting upstream kinases and regulators (TRAF3, CD40, BAFFR, and NIK) of this pathway, which promote NIK stability and subsequent activation of noncanonical NF‐κB, have been described in different cancer types [9, 10, 11, 12], including splenic marginal zone lymphomas, Hodgkin's lymphomas, and lung cancer.